LifeStance Health Group, Inc.
NASDAQ:LFSTMedical - Care Facilities
+$0.17 today
- Market cap
- $5.24B
- Beta
- 1.19
- P/E (TTM)
- 146.6
- EPS (TTM)
- $0.06
Volume 6.60M
Average 3.91M
LFST Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
LifeStance Health Group, Inc.NASDAQ: LFST
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $14.25M rose 1.7% year over year, ahead of the -5.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.
Context
- Depreciation & amortization amounted to 3.8% of revenue in FY2025, down 1.8 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of -5.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 54.75M USD
- Year-over-year change
- -22.8%
- 4-year CAGR
- +0.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.75M | -22.8% |
| FY2024 | 2024-12-31 | 70.95M | -11.8% |
| FY2023 | 2023-12-31 | 80.44M | +16.2% |
| FY2022 | 2022-12-31 | 69.2M | +27.8% |
| FY2021 | 2021-12-31 | 54.14M | — |
Depreciation & Amortization vs competitors
How LFST compares with its peers on the latest reported figures
- LFST's LTM Jun 2026 depreciation & amortization of $54.56M is the 5th largest of the 7 companies compared; the peer median is $133.07M.
- Its year-over-year change of -5.2% is the 5th highest of 7, against a peer median of +8.8%.
- Depreciation & amortization amounts to 3.4% of revenue for LFST, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $641.16M | +7.5% | +2.1% | 3.5% | |
| LTM Sep 2026 | $201.74M | +10.2% | +17.1% | 5.9% | |
| LTM Sep 2026 | $158.41M | -11.8% | -7.0% | 1.0% | |
| LTM Sep 2026 | $107.73M | +153.7% | +93.9% | 3.8% | |
| LTM Jun 2026 | $54.56M | -5.2% | -7.5% | 3.4% | |
| LTM Jun 2026 | $12.06M | +48.7% | +29.4% | 0.5% | |
| LTM Mar 2026 | $2.76M | -127.4% | -55.7% | 1.3% | |
| Peer median (excluding LFST) | $133.07M | +8.8% | +9.6% | 2.4% | |
Competitors are the stored peer set for LFST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (307.2M) | (215.56M) | (186.26M) | (57.44M) | 9.66M |
| Depreciation & Amortization | 54.14M | 69.2M | 80.44M | 70.95M | 54.75M |
| Deferred Income Tax | (26.95M) | (16.73M) | (21.92M) | (958K) | 2.42M |
| Stock-Based Compensation | 259.44M | 187.43M | 99.39M | 76.17M | 74.7M |
| Change in Working Capital | 2.14M | (16.94M) | (33.72M) | (27.37M) | (40.34M) |
| Accounts Receivables | (24.21M) | (21.66M) | (24.18M) | (6.4M) | 36.09M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 623K | 7.67M | (5.61M) | 501K | (1.56M) |
| Other Working Capital | 25.73M | (2.94M) | (3.94M) | (21.47M) | (74.87M) |
| Other Non-Cash Items | 27.85M | 45.4M | 45.2M | 45.91M | 44.96M |
| Operating Cash Flow | 9.42M | 52.79M | (16.88M) | 107.26M | 146.15M |
| Capital Expenditures | (94.49M) | (79.26M) | (40.52M) | (21.57M) | (36.13M) |
| Acquisitions (Net) | (99.58M) | (60.21M) | (19.82M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (194.08M) | (139.46M) | (60.34M) | (21.57M) | (36.13M) |
| Debt Repayment | (223.77M) | 69.56M | 55.28M | (1.69M) | (7.25M) |
| Common Stock Issued | 549.91M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (904K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.28M) | (21.39M) | (7.86M) | (8.26M) | (8.71M) |
| Financing Cash Flow | 313.86M | 47.26M | 47.43M | (9.95M) | (15.96M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 129.2M | (39.41M) | (29.8M) | 75.75M | 94.07M |
| Free Cash Flow | (85.07M) | (26.47M) | (57.4M) | 85.69M | 110.03M |
LifeStance Health Group, Inc.
NASDAQ:LFST
Intrinsic Alpha fair value
Locked
Current Price
$13.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.